Chronix Biomedical Adds Mass Sequencing Capabilities to Accelerate Development of its DNA Biomarkers
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Chronix Biomedical has reported that it has expanded and accelerated its biomarker development capabilities with the installation of Germany’s first high-throughput DNA mass sequencer at the University of Goettingen, Chronix’s long-time collaborator.
Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.
“The advent of next-generation mass sequencers is transformational for development of our biomarker discovery and detection programs, and we are delighted to have access to this state-of-the-art system in conjunction with our colleagues at the University of Goettingen,” said Dr. Ekkehard Schutz, vice president of research at Chronix Biomedical.
"Our proprietary technology has demonstrated excellent accuracy in the early detection of breast cancer and prostate cancer, and these new mass sequencing capabilities will allow us to rapidly develop tests for cancer and other chronic diseases.”
The new system allows Chronix to screen and analyze 25-times more genomes each month more cost-effectively than was possible with older methods. It has reduced the time needed to screen a genome by about 80%, while improving reproducibility of the results. The system has already enhanced the performance of Chronix’s initial tests for breast and prostate cancer, and is expected to accelerate development and commercialization efforts across the board.
“Access to this advanced mass sequencer will enable us to speed-up generation of the databases and related information that are prerequisites for development and commercialization of our apoptotic DNA biomarker technology,” noted Dr. Howard Urnovitz, CEO of Chronix. “The Chronix technology has shown early utility in several cancers and in CNS diseases such as multiple sclerosis and BSE. It has the potential to transform disease detection and monitoring, accelerate clinical research, enable development of companion diagnostics and help realize the goal of personalized disease management.”
Dr. Urnovitz continued, “Among the advantages of our approach are its versatility across applications and the fact that it is platform agnostic in regard to analytic systems. This flexibility means our technology can provide medically valuable ‘content’ in a wide variety of settings, and we intend to collaborate with a diverse group of partners to ensure its wide availability.”
Chronix researchers have developed proprietary diagnostic databases and related information using algorithms they developed to detect, analyze and identify disease-related fragments of DNA that are released into the bloodstream by apoptotic cells. This apoptotic DNA originates from a limited number of chromosomal regions, or “hotspots,” on the genome that are specific to each illness. By focusing on these genomic hotspots, the Chronix tests can reliably detect the presence of cancer without having first to isolate and analyze tumor cells, an important advantage.
"The tremendous increase in speed and cost-effectiveness the ABI SOLiD4 system provides is allowing us to dramatically accelerate development of the proprietary diagnostic databases and related information that are the foundation for our tests based on serum apoptotic DNA,” said. Dr. Julia Beck, Laboratory Manager at Chronix. “The platform agnostic flexibility of our technology allows us to select the hardware with the optimal performance criteria, and results to date with this highly automated sequencer are very encouraging."
Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.
“The advent of next-generation mass sequencers is transformational for development of our biomarker discovery and detection programs, and we are delighted to have access to this state-of-the-art system in conjunction with our colleagues at the University of Goettingen,” said Dr. Ekkehard Schutz, vice president of research at Chronix Biomedical.
"Our proprietary technology has demonstrated excellent accuracy in the early detection of breast cancer and prostate cancer, and these new mass sequencing capabilities will allow us to rapidly develop tests for cancer and other chronic diseases.”
The new system allows Chronix to screen and analyze 25-times more genomes each month more cost-effectively than was possible with older methods. It has reduced the time needed to screen a genome by about 80%, while improving reproducibility of the results. The system has already enhanced the performance of Chronix’s initial tests for breast and prostate cancer, and is expected to accelerate development and commercialization efforts across the board.
“Access to this advanced mass sequencer will enable us to speed-up generation of the databases and related information that are prerequisites for development and commercialization of our apoptotic DNA biomarker technology,” noted Dr. Howard Urnovitz, CEO of Chronix. “The Chronix technology has shown early utility in several cancers and in CNS diseases such as multiple sclerosis and BSE. It has the potential to transform disease detection and monitoring, accelerate clinical research, enable development of companion diagnostics and help realize the goal of personalized disease management.”
Dr. Urnovitz continued, “Among the advantages of our approach are its versatility across applications and the fact that it is platform agnostic in regard to analytic systems. This flexibility means our technology can provide medically valuable ‘content’ in a wide variety of settings, and we intend to collaborate with a diverse group of partners to ensure its wide availability.”
Chronix researchers have developed proprietary diagnostic databases and related information using algorithms they developed to detect, analyze and identify disease-related fragments of DNA that are released into the bloodstream by apoptotic cells. This apoptotic DNA originates from a limited number of chromosomal regions, or “hotspots,” on the genome that are specific to each illness. By focusing on these genomic hotspots, the Chronix tests can reliably detect the presence of cancer without having first to isolate and analyze tumor cells, an important advantage.
"The tremendous increase in speed and cost-effectiveness the ABI SOLiD4 system provides is allowing us to dramatically accelerate development of the proprietary diagnostic databases and related information that are the foundation for our tests based on serum apoptotic DNA,” said. Dr. Julia Beck, Laboratory Manager at Chronix. “The platform agnostic flexibility of our technology allows us to select the hardware with the optimal performance criteria, and results to date with this highly automated sequencer are very encouraging."
